BioRestorative Therapies, a clinical-stage company, announced that the U.S. Patent and Trademark Office has granted a notice of allowance for a patent application related to its innovative metabolic ThermoStem program. As a result, BioRestorative Therapies shares have surged by 14% to $1.98.
A Positive Turnaround
This recent development comes as welcome news for the company, which experienced a significant drop in its stock price over the past year, reaching a 52-week low of $1.41 on September 27. However, with this notice of allowance, BioRestorative Therapies is poised for a potential turnaround.
Expanding Patent Portfolio
Scheduled to be issued on December 26, this upcoming patent will mark the fourth U.S. patent granted under the specific patent family. The scope of the claims outlined in this new patent revolves around utilizing differentiated human brown fat adipocytes to screen and identify compounds that have the potential to activate and regulate metabolic activity.
A Promising Opportunity for Weight Loss
Through the discovery of these compounds, BioRestorative Therapies aims to explore their efficacy in providing metabolic benefits, with the ultimate goal of developing them into drugs specifically targeting weight loss.
For more information, please contact BioRestorative Therapies directly.
Retain original markdown formatting for remaining tags.
Leave a Reply